MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
14.72
-0.44 (-2.90%)
At close: Aug 1, 2025, 4:00 PM
14.65
-0.07 (-0.48%)
After-hours: Aug 1, 2025, 7:59 PM EDT
MiNK Therapeutics Employees
MiNK Therapeutics had 23 employees as of December 31, 2024. The number of employees decreased by 8 or -25.81% compared to the previous year.
Employees
23
Change (1Y)
-8
Growth (1Y)
-25.81%
Revenue / Employee
n/a
Profits / Employee
-$423,400
Market Cap
58.67M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23 | -8 | -25.81% |
Dec 31, 2023 | 31 | -6 | -16.22% |
Dec 31, 2022 | 37 | 4 | 12.12% |
Dec 31, 2021 | 33 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
INKT News
- 1 day ago - MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewsWire
- 17 days ago - MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - GlobeNewsWire
- 21 days ago - Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? - Benzinga
- 7 weeks ago - MiNK Therapeutics Announces Virtual Annual Shareholders Meeting - GlobeNewsWire
- 2 months ago - MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients - GlobeNewsWire
- 2 months ago - MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress - GlobeNewsWire
- 4 months ago - MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript - Seeking Alpha